Senseonics Holdings Inc (NYSEAMERICAN:SENS)’s share price fell 10.8% during mid-day trading on Thursday . The stock traded as low as $2.65 and last traded at $2.65. 3,555,995 shares were traded during trading, an increase of 98% from the average session volume of 1,792,478 shares. The stock had previously closed at $2.97.
SENS has been the topic of a number of analyst reports. Zacks Investment Research lowered Senseonics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 6th. Piper Jaffray Companies initiated coverage on Senseonics in a research report on Tuesday, January 29th. They issued a “neutral” rating on the stock. Finally, UBS Group initiated coverage on Senseonics in a report on Tuesday, November 27th. They issued a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $6.00.
Senseonics (NYSEAMERICAN:SENS) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.11. The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $7.89 million.
Senseonics Company Profile (NYSEAMERICAN:SENS)
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.